Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares traded -10.84% lower at $0.87 on Wall Street last session.
KPTI stock price is now -18.04% away from the 50-day moving average and -18.95% away from the 200-day moving average. The market capitalization of the company currently stands at $108.12M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $8, Piper Sandler recently initiated with Overweight rating for Karyopharm Therapeutics Inc (NASDAQ: KPTI). On November 04, 2022, RBC Capital Mkts Upgraded its previous ‘Sector Perform’ rating to ‘Outperform’ on the stock increasing its target price from $7 to quote $10, while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, PAKIANATHAN DEEPIKA, Director sold 231,548 shares of the company’s stock on Jun 07 ’24. The stock was sold for $220,133 at an average price of $0.95. Upon completion of the transaction, the Director now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 06 ’24, Director PAKIANATHAN DEEPIKA sold 118,452 shares of the business’s stock. A total of $116,415 was realized by selling the stock at an average price of $0.98. This leaves the insider owning 2,240 shares of the company worth $1948.8. A total of 12.36% of the company’s stock is owned by insiders.
During the past 12 months, Karyopharm Therapeutics Inc has had a low of $0.62 and a high of $1.95. The fifty day moving average price for KPTI is $1.04834 and a two-hundred day moving average price translates $1.068315 for the stock.
The latest earnings results from Karyopharm Therapeutics Inc (NASDAQ: KPTI) was released for 2024-03-31. The company reported revenue of $33.13 million for the quarter, compared to $38.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -14.4 percent.
